TimWalbert 2015Chairman, President and Chief Executive Officer, Horizon Pharma plc

Mr. Walbert joined Horizon Pharma in June 2008 as our president and chief executive officer and has served as chairman of our board of directors since 2010. Prior to joining Horizon Pharma, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Mr. Walbert served as executive vice president, commercial operations at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, Mr. Walbert served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College, in Allentown, Pennsylvania. Mr. Walbert serves on the board of directors of XOMA Corporation (NASDAQ: XOMA), Egalet Corporation (NASDAQ: EGLT), the Biotechnology Industry Organization (BIO), the Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT, a World Business Chicago (WBC) led council of technology leaders and the Greater Chicago Arthritis Foundation. Mr. Walbert is also a member of the Illinois Innovation Council.


Senior Vice President, Research & External Scientific Innovation, Allergan

Don has more than 25 years of experience in the pharmaceutical industry and currently leads all research activities and the scientific search and evaluation team for in-licensing and partnering opportunities at Allergan. Previously at AstraZeneca his team initiated clinical programs through drug repurposing and implemented groundbreaking partnerships with the Medical Research Council UK and National Institutes of Health to collaborate with investigators to explore the use of AZ development compounds in new indications. Don also co-authored the book ”Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs”. Don has held several leadership positions, including founder and CSO of the Indications Discovery Unit at Pfizer, Head of Pfizer’s St. Louis R&D site, VP of Biology for the St. Louis site, and head of Discovery Neurosciences in Pharmacia."

AlanGoldberg picContractor, Conceptual Mindworks Inc.

Alan Goldberg has been working in pharmaceutical and related industries for over 40 years. For most of that time he has led project teams involved with pharmaceutical product development leading to multiple marketing approvals in several therapeutic areas. He has created and led Project Management Organizations in both industry and non-profits. Alan has received advanced degrees in both Chemistry and Business. Alan is currently a Contractor with Conceptual Mindworks Inc. supporting HHS/ U.S. Government.

Ben Katz photo

Managing Director at HSBC Securities
Social Finance Chair

Ben Katz is an international investment banker specializing in capital raising from fixed income investors and enterprise risk management using interest rate and foreign exchange derivatives to manage risk.  From 1996 through 2010 Ben advised UK and Western European financial institutions and insurance companies and subsequently to the same type of US, Canadian and Bermudian companies. 

Stephen NaylorFounder, Chairman and CEO, MaiHealth

Stephen has over 25 years of experience in the Health and Life Sciences in both the academic and private sectors.  In addition, he is also the founder and served as Executive Management /Chairman of numerous other companies in the personalised medicine, diagnostic, companion diagnostic, biomarker and systems biology sectors.  He has published over 250 scientific journal manuscripts, filed over 20 patents and helped raise in excess of $40 million in federal grants (NIH/SBIR) and $40 million in equity investments for the companies he has been associated with over the past decade.  Stephen has degrees from the University of East Anglia (BSc-1st Class Honors-Chemistry), University of Southampton (MSc-Oceanography), University of California (MS-Chemical Sciences) and University of Cambridge (PhD-Analytical Biochemistry /Chemistry) and also was a Postdoctoral Fellow at MIT.  Over the years he has worked at the MRC (UK), Mayo Clinic (US) and the world’s first systems biology company Beyond Genomics, as well as helped found numerous small start up entities, all in the US.

NorbertRiedelexecportrait2009 011President and Chief Executive Officer, Aptinyx

Dr. Riedel is president and CEO of Aptinyx, as well as a member of the company’s board of directors. He was formerly president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, Dr. Riedel was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). Dr. Riedel serves on the boards of Jazz Pharmaceuticals and the Illinois Biotechnology Industry Organization.

BrianRoden picSenior Partner, GreenField Chemical

Brian has 25 years experience in the development of branded and generic pharmaceutical products.  Prior to GreenField, a pharmaceutical life cycle management consulting firm, he was a senior consultant for Newport Consulting specializing in pharmaceutical life cycle management.  Previously, Brian was with Abbott Laboratories where he was responsible for the technical support groups for active pharmaceutical ingredient (API) manufacture at the former Abbott North Chicago site. He has experience in supply chain management where he was responsible for negotiating ~$75 million in API raw material supply contracts.  


Rosen BioScience Strategies

Michael S. Rosen is Senior Vice President, New Business Development for the Science + Technology Group at Forest City Enterprises, a NYSE-traded national real estate development company which develops and builds bioscience parks across the U.S.  Mr. Rosen works with key research universities affiliated with Forest City bioparks, such as Northwestern University in Chicago, Johns Hopkins University in Baltimore and MIT in Boston, and endeavors to bring life science companies from Europe, Asia, Latin America, India, Israel, and Canada into these parks.

AdriannSax photoEntrepreneur in Residence, Fortress Biotech

Adriann is an Entrepreneur in Residence at Fortress Biotech, a public biotech company which finds and forms subsidiary companies around promising drugs and technologies. For more than 25 years, Adriann has been a global biotech and pharmaceutical industry leader managing all stages of drug development, commercialization, strategic deal-making and partnerships. Prior to Fortress Biotech, Adriann was Executive Vice President, Chief Commercial Officer of Kadmon Corporation leading Kadmon’ s commercial organization, Kadmon Pharmaceuticals, from its inception in September 2010.

Before Kadmon, Adriann was Executive Vice President, Business Development and Strategic Planning at King Pharmaceuticals where she led many profitable transactions in addition to creating and implementing King’s Corporate Strategy for Growth in 2005, contributing to the company’s overall success and ultimate sale to Pfizer in 2011.

Nancy SullivanCEO and Senior Managing Director, IllinoisVENTURES

Nancy Sullivan serves as the CEO and Managing Director of IllinoisVENTURES, LLC and the Executive Director of the Office of Technology Management at the University of Illinois at Chicago. With over 10 years of experience in the commercialization and entrepreneurial sector, Nancy leads the IllinoisVENTURES, LLC economic development and seed stage investment portfolio.

Nancy promotes the development of new companies commercializing university technologies by assisting the companies in obtaining seed and venture capital funding, recruiting management talent and obtaining necessary business services. She serves as a valuable link to regional and national venture capital and angel networks to enhance Illinois company formation.


Retired Executive Vice President, Abbott

James L. Tyree has a distinguished career in health care spanning more than thirty years. His accomplishments are well recognized as an investor, operating executive, and entrepreneur. During the last fifteen years, he has held numerous executive positions at Abbott including Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development, Senior Vice President Global Nutrition, Executive Vice President Global Pharmaceuticals, and President Abbott Biotech Ventures.

Sign up for our eNewsletter today!


First Name


Cures Within Reach

Illinois Science+Technology Park

8025 Lamon Avenue, Suite 440

Skokie, IL 60077




Friday the 22nd. copyright 2015 Cures Within Reach.